COVID-19 induces acute and long-term neurological symptoms. Determining the mechanisms underlying acute neurological disease will lead to a better understanding of long-COVID and late-onset outcomes. Here, we investigate in detail a cohort of COVID-19 patients presenting neurological alterations. Clinical and neurological investigation, brain imaging, and bio-sample analyses were carried out. We tested the possibility that COVID-19 shares molecular links with Alzheimer’s disease (AD)-like neurodegeneration by analyzing the framework of ATN (amyloid, pathologic Tau, and neurodegeneration) biomarkers. Altered cerebrospinal fluid (CSF) Tau and amyloid levels in severe COVID-19 patients were comparable to amnestic mild cognitive impairment (aMCI) and AD patients. Increased CSF pro-inflammatory cytokine IL6 and Tau linked systemic inflammation and disease severity to central nervous system alterations. COVID-19 patients presented an altered CSF proteomic pattern, with inflammatory, coagulopathy, and amyloidosis pathways alterations. Collectively, our findings reveal some molecular links between COVID-19 neurological disease and neurodegeneration biomarkers associated with AD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.